Literature DB >> 19903812

Proline is not uniquely capable of providing the pivot point for domain swapping in 2G12, a broadly neutralizing antibody against HIV-1.

Johannes S Gach1, Paul G Furtmüller, Heribert Quendler, Paul Messner, Ralf Wagner, Hermann Katinger, Renate Kunert.   

Abstract

The human monoclonal antibody 2G12 is a member of a small group of broadly neutralizing antibodies against human immunodeficiency virus type 1. 2G12 adopts a unique variable heavy domain-exchanged dimeric configuration that results in an extensive multivalent binding surface and the ability to bind with high affinity to densely clustered high mannose oligosaccharides on the "silent" face of the gp120 envelope glycoprotein. Here, we further define the amino acids responsible for this extraordinary domain-swapping event in 2G12.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19903812      PMCID: PMC2801240          DOI: 10.1074/jbc.M109.058792

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

Review 1.  Unraveling hot spots in binding interfaces: progress and challenges.

Authors:  Warren L DeLano
Journal:  Curr Opin Struct Biol       Date:  2002-02       Impact factor: 6.809

Review 2.  3D domain swapping: as domains continue to swap.

Authors:  Yanshun Liu; David Eisenberg
Journal:  Protein Sci       Date:  2002-06       Impact factor: 6.725

3.  Electron microscopic and immunochemical analysis of the broadly neutralizing HIV-1-specific, anti-carbohydrate antibody, 2G12.

Authors:  K H Roux; Ping Zhu; Margaret Seavy; Hermann Katinger; Renate Kunert; Vanessa Seamon
Journal:  Mol Immunol       Date:  2004-08       Impact factor: 4.407

4.  Coot: model-building tools for molecular graphics.

Authors:  Paul Emsley; Kevin Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-11-26

5.  Identical V region amino acid sequences and segments of sequences in antibodies of different specificities. Relative contributions of VH and VL genes, minigenes, and complementarity-determining regions to binding of antibody-combining sites.

Authors:  E A Kabat; T T Wu
Journal:  J Immunol       Date:  1991-09-01       Impact factor: 5.422

6.  Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG.

Authors:  A Trkola; A B Pomales; H Yuan; B Korber; P J Maddon; G P Allaway; H Katinger; C F Barbas; D R Burton; D D Ho
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

7.  Hypochlorite-modified high-density lipoprotein acts as a sink for myeloperoxidase in vitro.

Authors:  Gunther Marsche; Paul G Furtmüller; Christian Obinger; Wolfgang Sattler; Ernst Malle
Journal:  Cardiovasc Res       Date:  2008-02-23       Impact factor: 10.787

8.  Crystal structure of the complex between the F(ab)' fragment of the cross-neutralizing anti-HIV-1 antibody 2F5 and the F(ab) fragment of its anti-idiotypic antibody 3H6.

Authors:  Steve Bryson; Jean-Philippe Julien; David E Isenman; Renate Kunert; Hermann Katinger; Emil F Pai
Journal:  J Mol Biol       Date:  2008-07-27       Impact factor: 5.469

9.  A glycoconjugate antigen based on the recognition motif of a broadly neutralizing human immunodeficiency virus antibody, 2G12, is immunogenic but elicits antibodies unable to bind to the self glycans of gp120.

Authors:  Rena D Astronomo; Hing-Ken Lee; Christopher N Scanlan; Ralph Pantophlet; Cheng-Yuan Huang; Ian A Wilson; Ola Blixt; Raymond A Dwek; Chi-Huey Wong; Dennis R Burton
Journal:  J Virol       Date:  2008-04-23       Impact factor: 5.103

10.  Antibody domain exchange is an immunological solution to carbohydrate cluster recognition.

Authors:  Daniel A Calarese; Christopher N Scanlan; Michael B Zwick; Songpon Deechongkit; Yusuke Mimura; Renate Kunert; Ping Zhu; Mark R Wormald; Robyn L Stanfield; Kenneth H Roux; Jeffery W Kelly; Pauline M Rudd; Raymond A Dwek; Hermann Katinger; Dennis R Burton; Ian A Wilson
Journal:  Science       Date:  2003-06-27       Impact factor: 47.728

View more
  8 in total

1.  Very few substitutions in a germ line antibody are required to initiate significant domain exchange.

Authors:  Michael Huber; Khoa M Le; Katie J Doores; Zara Fulton; Robyn L Stanfield; Ian A Wilson; Dennis R Burton
Journal:  J Virol       Date:  2010-08-11       Impact factor: 5.103

2.  Interrogation of side chain biases for oligomannose recognition by antibody 2G12 via structure-guided phage display libraries.

Authors:  Tsung-Yi Lin; Jonathan R Lai
Journal:  Bioorg Med Chem       Date:  2017-09-15       Impact factor: 3.641

3.  Internalization of HIV-1 by Phagocytes Is Increased When Virions Are Opsonized with Multimeric Antibody in the Presence of Complement.

Authors:  Johannes S Gach; Stephanie Y Matsuno; Mayalen Mercado; Lars Hangartner; Donald N Forthal
Journal:  J Virol       Date:  2021-11-03       Impact factor: 6.549

4.  Introduction of germline residues improves the stability of anti-HIV mAb 2G12-IgM.

Authors:  Veronika Chromikova; Alexander Mader; Stefan Hofbauer; Christoph Göbl; Tobias Madl; Johannes S Gach; Stefan Bauernfried; Paul G Furtmüller; Donald N Forthal; Lukas Mach; Christian Obinger; Renate Kunert
Journal:  Biochim Biophys Acta       Date:  2015-03-05

5.  Identification of CD4-Binding Site Dependent Plasma Neutralizing Antibodies in an HIV-1 Infected Indian Individual.

Authors:  Lubina Khan; Muzamil Ashraf Makhdoomi; Sanjeev Kumar; Ambili Nair; Raiees Andrabi; Brenda E Clark; Kate Auyeung; Jayanta Bhattacharya; Madhu Vajpayee; Naveet Wig; Ralph Pantophlet; Kalpana Luthra
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

6.  A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1.

Authors:  Johannes S Gach; Heribert Quendler; Tommy Tong; Kristin M Narayan; Sean X Du; Robert G Whalen; James M Binley; Donald N Forthal; Pascal Poignard; Michael B Zwick
Journal:  PLoS One       Date:  2013-08-26       Impact factor: 3.240

7.  HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study.

Authors:  Johannes S Gach; Chad J Achenbach; Veronika Chromikova; Baiba Berzins; Nina Lambert; Gary Landucci; Donald N Forthal; Christine Katlama; Barbara H Jung; Robert L Murphy
Journal:  PLoS One       Date:  2014-01-15       Impact factor: 3.752

8.  HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects.

Authors:  Johannes S Gach; Andrea Gorlani; Emmanuel Y Dotsey; Juan C Becerra; Chase T M Anderson; Baiba Berzins; Philip L Felgner; Donald N Forthal; Steven G Deeks; Timothy J Wilkin; Joseph P Casazza; Richard A Koup; Christine Katlama; Brigitte Autran; Robert L Murphy; Chad J Achenbach
Journal:  PLoS One       Date:  2016-08-08       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.